CervoMed completes enrollment in Phase 2b neflamapimod trial for DLB; topline data due Dec 2024

CervoMed Inc.

Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB) fully enrolled.
Topline data expected in December 2024 (16-week double-blind placebo-controlled period).
Trial targets up to 160 patients; excludes AD co-pathology via plasma ptau181 screen (two-thirds eligible).
Primary endpoint: Clinical Dementia Rating Sum of Boxes; funded by $21M NIH/NIA grant.
43 sites (32 US, 8 UK, 3 Netherlands) all initiated; open-label extension for 32 additional weeks.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.